ATNX ATNX

Athenex Stock Price

0.455
-0.0374 (-7.6%)
Upgrade to Real-Time
Afterhours (Closed)
0.455
Volume 2,540,449
Bid Price 0.4512
Ask Price 0.455
News -
Day High 0.49

Low
0.4051

52 Week Range

High
3.91

Day Low 0.4501
Company Name Stock Ticker Symbol Market Type
Athenex Inc ATNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0374 -7.6% 0.455 19:59:22
Open Price Low Price High Price Close Price Prev Close
0.49 0.4501 0.49 0.4566 0.4924
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,522 2,540,449 $ 0.4692713 $ 1,192,160 - 0.4051 - 3.91
Last Trade Time Type Quantity Stock Price Currency
19:59:39 formt 5,000 $ 0.455 USD

Period:

Draw Mode:

Athenex Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 55.33M 121.61M 99.73M $ 120.18M $ - -1.92 -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.28M 6.00%

more financials information »

Athenex News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.550.5650.45010.51623113,279,113-0.095-17.27%
1 Month0.6771.190.45010.69652393,736,675-0.222-32.79%
3 Months0.4941.190.40510.61964062,163,595-0.039-7.89%
6 Months0.801.200.40510.65733141,458,274-0.345-43.13%
1 Year3.263.910.40511.371,273,938-2.81-86.04%
3 Years15.7122.000.40515.801,516,475-15.26-97.1%
5 Years15.3122.000.40517.111,056,146-14.86-97.03%

Athenex Description

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Your Recent History
NASDAQ
ATNX
Athenex
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220820 03:34:42